Legacy Portfolio — Total Revenues
Bristol-Myers Squibb Legacy Portfolio — Total Revenues decreased by 5.4% to $5.37B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 11.8%, from $6.08B to $5.37B. Over 2 years (FY 2022 to FY 2024), Legacy Portfolio — Total Revenues shows a downward trend with a -6.4% CAGR.
Analysis
How to read this metric
A decrease in revenue is expected as products age and face generic competition, while a stable or slow-declining trend indicates effective lifecycle management and cash-flow preservation.
Detailed definition
This metric represents the aggregate revenue generated from established pharmaceutical products that have passed their p...
Peer comparison
Peers in the pharmaceutical industry typically report this as 'Established Brands' or 'Mature Products' revenue, which is generally expected to decline as a percentage of total sales over time.
bmy_segment_legacy_portfolio_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.35B | $7.35B | $7.35B | $7.35B | $6.92B | $6.48B | $6.02B | $6.22B | $7.07B | $6.61B | $6.08B | $5.98B | $5.64B | $5.67B | $5.37B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -5.9% | -6.3% | -7.1% | +3.3% | +13.8% | -6.6% | -7.9% | -1.7% | -5.7% | +0.6% | -5.4% |
| YoY Change | — | — | — | — | -5.9% | -11.8% | -18.1% | -15.4% | +2.2% | +1.9% | +1.0% | -3.8% | -20.3% | -14.1% | -11.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's legacy portfolio — total revenues?
- Bristol-Myers Squibb (BMY) reported legacy portfolio — total revenues of $5.37B in Q3 2025.
- How has Bristol-Myers Squibb's legacy portfolio — total revenues changed year-over-year?
- Bristol-Myers Squibb's legacy portfolio — total revenues decreased by 11.8% year-over-year, from $6.08B to $5.37B.
- What is the long-term trend for Bristol-Myers Squibb's legacy portfolio — total revenues?
- Over 2 years (2022 to 2024), Bristol-Myers Squibb's legacy portfolio — total revenues has grown at a -6.4% compound annual growth rate (CAGR), from $29.40B to $25.74B.
- What does legacy portfolio — total revenues mean?
- The total sales generated by the company's older, mature pharmaceutical products.